The Finnish group which markets these tests announces that it will be able to cover global needs until one of the components of these tests is re-supplied.
Published
Reading time :
1 minute
:quality(50)/2023/09/13/080-hl-jleblois-2022213-65020d153b025190774278.jpg)
The drug agency says it is looking for “alternatives” to overcome these supply difficulties. The Finnish group Perkin Elmer, which markets medical tests used to detect Down syndrome during pregnancy, reported a “global supply tension” specifies the French National Medicines Safety Agency (ANSM) in a press release published Wednesday September 13.
These difficulties can be explained “due to a disruption in supply of one of their components”, continues the ANSM. The Finnish group claims to be able to “cover global needs” up to one “back to normal” expected in 2024.
Nevertheless, the ANSM claims to be mobilized to “reduce the potential impact” of these supply tensions and “guarantee access to this screening for all pregnant women”. This screening test is one of the most commonly performed during pregnancy.